Nutritional education and counseling program for adult cancer patients during radiotherapy: a cluster-randomized clinical trial

2022 ◽  
Author(s):  
Zhihong Zhang ◽  
Yu Zhu ◽  
Lijuan Zhang ◽  
Ziying Wang ◽  
Zhonghua Fu ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Randomized Clinical Trial ◽  
Cancer Patients ◽  
Counseling Program ◽  
Nutritional Education ◽  
Cluster Randomized

scholarly journals Using increased trust in medical researchers to increase minority recruitment: The RECRUIT cluster randomized clinical trial

2021 ◽  
pp. 106519
Author(s):  
Barbara C. Tilley ◽  
Arch G. Mainous ◽  
Rossybelle P. Amorrortu ◽  
M. Diane McKee ◽  
Daniel W. Smith ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Randomized Clinical Trial ◽  
Minority Recruitment ◽  
Medical Researchers ◽  
Cluster Randomized

scholarly journals Comparing the efficacy and side-effects of PDLASTA® (Pegfilgrastim) with PDGRASTIM® (Filgrastim) in breast cancer patients: a non-inferiority randomized clinical trial

BMC Cancer ◽  
2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Safa Najafi ◽  
Maryam Ansari ◽  
Vahid Kaveh ◽  
Shahpar Haghighat
Keyword(s):  
Breast Cancer ◽  
Clinical Trial ◽  
Single Dose ◽  
Side Effects ◽  
Randomized Clinical Trial ◽  
Cancer Patients ◽  
Injection Site Reaction ◽  
Study Groups ◽  
Breast Cancer Patients ◽  
Significant Difference

Abstract Background The objective of this study was to compare the efficacy and side effects of a single dose (Pegfilgrastim or PDL) or repeated six daily injections (Filgrastim or PDG) during chemotherapy courses in breast cancer patients in a non-inferiority clinical trial. Methods In this randomized clinical trial, 80 patients were recruited and allocated randomly to two equal arms. In one group, a single subcutaneous dose of PDL was injected the day after receiving the chemotherapy regimen in each cycle. The second arm received a subcutaneous injection of PDG for six consecutive days in each cycle of treatment. The side effects of GCF treatment and its effect on blood parameters were compared in each cycle and during eight cycles of chemotherapy. Results Hematologic parameters showed no significant differences in any of the treatment courses between the two study groups. The comparison of WBC (p = 0.527), Hgb (p = 0.075), Platelet (p = 0.819), Neutrophil (p = 0.575), Lymphocyte (p = 705) and ANC (p = 0.675) changes during the eight courses of treatment also revealed no statistically significant difference between the two study groups. Side effects including headache, injection site reaction and muscle pain had a lower frequency in patients receiving PDL drugs. Conclusion It seems that PDL is non-inferior in efficacy and also less toxic than PDG. Since PDL can be administered in a single dose and is also less costly, it can be regarded as a cost-effective drug for the treatment of chemotherapy-induced neutropenia. Trial registration IRCT20190504043465N1, May 2019.

scholarly journals Randomized clinical trial of an individualized intervention promotes cancer patients’ prognostic awareness and reduces CPR received in the last month

2018 ◽  
Vol 29 ◽  
pp. viii549
Author(s):  
C.H. Chen ◽  
J.-S. Chen ◽  
F.H. Wen ◽  
J.W.-C. Chang ◽  
W.-C. Chou ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Randomized Clinical Trial ◽  
Cancer Patients ◽  
Individualized Intervention

Is the future for clinical trials internet-based? A cluster randomized clinical trial

2005 ◽  
Vol 2 (1) ◽  
pp. 72-79 ◽  
Author(s):  
Jennifer Litchfield ◽  
Jenny Freeman ◽  
Henrik Schou ◽  
Mark Elsley ◽  
Robert Fuller ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Clinical Trials ◽  
Randomized Clinical Trial ◽  
The Future ◽  
Cluster Randomized
Sign in / Sign up

Export Citation Format

Share Document